Lumos Pharma Inc (LUMO)
2.251
0.00 (0.00%)
USD |
NASDAQ |
Jun 27, 16:00
2.26
+0.01
(+0.39%)
After-Hours: 20:00
Lumos Pharma Enterprise Value: -4.907M for June 27, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 27, 2024 | -4.907M |
| June 26, 2024 | -4.876M |
| June 25, 2024 | -4.998M |
| June 24, 2024 | -4.754M |
| June 21, 2024 | -5.079M |
| June 20, 2024 | -5.404M |
| June 18, 2024 | -5.323M |
| June 17, 2024 | -4.511M |
| June 14, 2024 | -3.781M |
| June 13, 2024 | -2.969M |
| June 12, 2024 | -2.320M |
| June 11, 2024 | -2.482M |
| June 10, 2024 | -3.618M |
| June 07, 2024 | -3.050M |
| June 06, 2024 | -2.807M |
| June 05, 2024 | -4.105M |
| June 04, 2024 | -4.754M |
| June 03, 2024 | -4.511M |
| May 31, 2024 | -4.917M |
| May 30, 2024 | -4.592M |
| May 29, 2024 | -4.430M |
| May 28, 2024 | -4.430M |
| May 24, 2024 | -3.286M |
| May 23, 2024 | -2.888M |
| May 22, 2024 | -2.320M |
| Date | Value |
|---|---|
| May 21, 2024 | -2.725M |
| May 20, 2024 | -1.914M |
| May 17, 2024 | -2.563M |
| May 16, 2024 | -1.833M |
| May 15, 2024 | -4.998M |
| May 14, 2024 | -2.482M |
| May 13, 2024 | 0.1559M |
| May 10, 2024 | 0.3589M |
| May 09, 2024 | 1.333M |
| May 08, 2024 | 1.171M |
| May 07, 2024 | 1.333M |
| May 06, 2024 | 1.170M |
| May 03, 2024 | 0.8458M |
| May 02, 2024 | 1.495M |
| May 01, 2024 | 1.333M |
| April 30, 2024 | -0.3716M |
| April 29, 2024 | -0.2093M |
| April 26, 2024 | -0.6963M |
| April 25, 2024 | -0.7775M |
| April 24, 2024 | -0.4934M |
| April 23, 2024 | -0.4528M |
| April 22, 2024 | -1.427M |
| April 19, 2024 | -2.157M |
| April 18, 2024 | -1.914M |
| April 17, 2024 | -2.725M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-57.92M
Minimum
Jun 28 2019
197.90M
Maximum
Dec 31 2020
-7.957M
Average
-16.25M
Median
Jan 28 2022
Enterprise Value Benchmarks
| icad Inc | 14.22M |
| Perspective Therapeutics Inc | 486.45M |
| Palatin Technologies Inc | 20.65M |
| Bio-Path Holdings Inc | 3.042M |
| PDS Biotechnology Corp | 67.71M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.44M |
| Revenue (Quarterly) | 0.165M |
| Total Expenses (Quarterly) | 11.03M |
| EPS Diluted (Quarterly) | -1.29 |
| Profit Margin (Quarterly) | -6.33K% |
| Earnings Yield | -243.4% |
| Normalized Earnings Yield | -243.43 |